Dole raises 2025 earnings guidance despite ‘unpredictable' economic environment
Dole raises 2025 earnings guidance despite 'unpredictable' economic environment
Vish Gain
12:43
The group formed in 2021 through the merger of between a Dublin-based Fyffes spin-out and US-based Dole Food Company.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
4 hours ago
- Irish Times
Gareth Sheridan: Nutriband ‘will help a lot of people who are dealing with addiction and people who are dealing with pain'
Nutriband is a pharmaceutical company that was founded in Dublin in 2012 before relocating to Florida in 2016. Gareth Sheridan, who recently announced his intention to run for president and has stepped aside for three months as chief executive, is its founder. The company's lead product is Aversa, which it describes as 'abuse-deterrent transdermal technology', which incorporates aversive agents to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, specifically opioids. Its first application is its abuse-deterrent fentanyl transdermal patch, which it is developing to provide clinicians and patients with extended-release chronic pain relief. It is awaiting regulatory clearance for this product in the US. The company has operations in Florida, Georgia, and North Carolina, and recently began its expansion back to Dublin. READ MORE What lightbulb moment prompted you to start-up in business? It was originally a thesis idea. I had noticed a patch that my dad wears and began wondering what other types of medications could be delivered that way that had not been explored yet. The thesis became a business plan, and Nutriband was registered in 2012. Describe your business model and what makes your business unique. We structured the company in a unique way, using capital markets and a public listing approach. We listed on the OTC Markets in 2016 and started using stock to purchase companies and technologies in place of cash. This helped us to avoid raising expensive early capital and retain a major equity stake in the company today, even after an eventual qualification to list on the Nasdaq (in New York) in 2010. We also do not develop new drug applications. We take existing generic medications and use our technologies to improve upon those and relaunch them as a branded product again. What is your greatest business achievement to date? Growing the company to a level where we qualified to list on the Nasdaq Stock Exchange and getting to ring the opening bell. What was your back-to-the-wall moment and how did you overcome it? We almost got sued by the SEC (The US Securities and Exchange Commission) for an accidental erroneous disclosure in one of our filings while on the OTC markets. At first, we thought it could be explained. However, it grew to the point where they were doubling down. We hired an excellent attorney with SEC experience and eventually settled the issue in a cease-and-desist, no-admit, no-deny agreement. This led to our back-to-the-wall moment, where, while running on fumes financially, we received a rejection from Nasdaq in our first application. After a couple of days of self-pity, we got back to work, raised some working capital with existing shareholders, and grew the company's equity by $7.5 million (€6.4 million) over the course of the next year. We reapplied to list again successfully. What moment would you cite as a turning point for the company? Credibility provided by our Nasdaq listing and subsequent partnership with Kindeva Drug Delivery (formerly 3M Drug Delivery), where Kindeva supplied their generic approved fentanyl patch for us to add our technology to. What were the best and the worst pieces of advice you received when starting out? The worst advice was that banks and institutions have your company's best interests at heart. I firmly believe that today, Wall Street is built on companies failing, not succeeding. Describe your growth funding path. We were reluctant to raise expensive capital early on and instead listed the company to use stock as an acquisition currency to grow. Our gamble on this paid off, and although we raised modest cash along the way, we were able to build Nutriband without any significant seed or angel rounds. We reached a market capitalisation of $120 million (its market value currently is about $75 million), and we have been able to maintain stable and steady control as a result of the minimal capital rounds. We turn down anywhere from $5 million to $15 million on a weekly basis from funds and institutions because we do not need it. We are not in the business of raising money, and having as little dilution as possible is a core focus for us as a company. How will your market look in three years and where would you like your business to be? For our first product, we are expected to reach annual revenues of $200 million. Our second product is independently estimated to have upwards of $135 million in yearly revenue. We are targeting the billion dollar club before the end of 2027. What are your annual revenues and profits? We are not yet profitable, as is typical with clinical development-stage companies. However, we also contract manufacture sports tapes and products for brands such as Reebok and KT Tape. Our target revenue from this source for the financial year to the end of January 2026 is $3 million * . This goes towards operational costs and reduces our clinical burn. Why have you decided to seek a nomination for the presidency? It's never been a more important or relevant time in our history for a young president, particularly with the average age just under 40. I would be hoping that having a younger president would help narrow the division we're seeing in the country at the moment and that we can work together to tackle the issues, particularly the housing crisis. The younger generation aren't feeling very enthusiastic that their voices are being heard. What impact will this move have on your business? The company is in very safe hands and the biggest asset at the company is the team. We've got a very definite plan and timeline between now and Christmas on what needs to be achieved. Whether I'm in there or not that timeline needs to be adhered to. The company is motoring along fine. Stepping aside is not something that I think will fundamentally affect the opportunity for the company. What happens if you win? There are mechanisms where I can put the shares into a trust. I would be very proud that it was a company that I started and be very keen to still follow the journey, just not as CEO. Nutriband as a whole is going to do a lot of will help a lot of people who are dealing with addiction and people who are dealing with pain. *An earlier version of this article stated a higher target figure for contract manufacturing, which has since been revised by the company.
RTÉ News
10 hours ago
- RTÉ News
Ceasefire, sanctions avoided in win-win summit for Putin
The summit was a win-win for Russian President Vladimir Putin. Not only has he managed to avoid US sanctions being imposed on Russia and secondary tariffs on its trading partners, as US President Donald Trump had threatened only a week ago, it now appears that he has convinced the US President that a ceasefire is not necessary to end the war in Ukraine. Mr Trump's latest comment on Truth Social said it all: "The best way to end the horrific war between Russia and Ukraine is to go directly to a Peace Agreement, which would end the war, and not a mere Ceasefire Agreement." Going straight to a peace agreement jettisons, what has been until now, a shared US, Ukrainian and European policy that a ceasefire must be agreed first before any substantial peace talks take place on the key issue of occupied territory. Russia opposed US ceasefire proposals in March and April so the logical conclusion is that Mr Putin convinced Mr Trump during their three-hour meeting to drop the idea of a ceasefire. We can expect Mr Trump to place pressure on Ukrainian President Volodymyr Zelensky to agree to entering peace talks soon when they meet in Washington on Monday. Only last Tuesday all EU member states except Hungary endorsed a statement that only "meaningful negotiations" can take place "in the context of a ceasefire or reduction of hostilities". The UK shares the same position. Mr Trump's 180-degree turn will cause unease in Europe but it is hard to see how European leaders can now bring the conversation back to the need to first establish a ceasefire. Mr Putin also managed to make the summit more about US-Russia relations and shared business opportunities, rather than Ukraine. Yesterday's press conference in Alaska lasted all of 12 minutes and journalists were granted no questions. Mr Putin spoke for nine of those minutes, and delivered a rambling historical narrative about Alaska's Russian heritage and US-Russian cooperation during World War II. No one had come to hear that. When he did briefly mention, what he termed, "the situation around Ukraine", he stuck to his familiar script. "We need to eliminate all the primary roots, the primary causes of that conflict, and we've said it multiple times," he said. So Mr Trump's promise on Thursday to enact "very severe consequences" on Russia if it did not agree to a ceasefire during the Alaska meeting has come to nothing. Instead, Russia's leader has come away from the summit with a commitment to go straight to peace talks and that does not bode well for Ukraine.
Irish Times
10 hours ago
- Irish Times
The Irish Times view on Budget 2026: put the focus on what is important
Over the next couple of weeks, as the Autumn political season starts to kick in, debate on October's budget will get underway in earnest. As ever, there will be a cacophony of demands from interest groups and lobbyists, looking for more spending or lower taxes for their particular cause. The job of the Government, of course, is to look through the noise to what is important. Despite the generous amount of €9.4 billion set aside for budget measures, this will not be easy. Money will be quickly eaten up through spending pressures in providing State services. Plans to hike vital investment expenditure need to be allowed for. And the demands on the table already would take up the €1.5 billion set aside for tax reductions a few times over. Yet while the choices will be sharp in some areas, context is needed. This is not shaping up to be a 'tough' budget. The promised package is still nearly three times the size of the last pre-Covid budget in 2019. The first job of the Government, indeed, is to start returning annual budgets to more sustainable levels, reducing them from the huge spending rises required during Covid-19 and to tackle the cost-of-living crisis. Claims that households are still squeezed need to be met in two ways. One is by appropriate increases in welfare and other support packages. The other is by continuing to improve the provision of services in areas such as health, education and childcare. These are much more effective in the longer-term than another round of universal cash supports. But by engaging in a blatant pre-election manoeuvre last year to repeat these 'once-off' supports again, Ministers have created a rod for their own back this time around. READ MORE Statements from Ministers that there would be no cost-of-living package this time appear to have become more equivocal in recent weeks. But giving a lot of money out again through these payments to all households is an inefficient use of State cash. If the Government does not bring this process to an end in the first budget of its new term, then – barring a big squeeze on the State finances – it never will. The plan to increase vital State investment is a key reason why there needs to be some restraint elsewhere. Realistic budgeting for the provision of State services also needs to be restored, ending the annual overruns in areas like health. Relying on corporate tax to keep outperforming as a way to pay for spending coming in ahead of target each year is not a good strategy. The other reason for caution is the uncertainty faced due to the policies of Donald Trump. Despite the trade deal between the EU and US, the economic and political backdrop for Ireland remains risky and unpredictable. Having cash in reserve and pursuing a strategic approach have seldom looked more important.
